Ligand Pharmaceuticals Incorporated provided revenue guidance for the year 2022. The company expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million. These revenue components result in total revenue of $147 million to $172 million for the combined Ligand business.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
84.94 USD | +0.80% |
|
+6.45% | +19.18% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.18% | 151.36Cr | |
+56.62% | 82TCr | |
+43.90% | 64TCr | |
-6.75% | 35TCr | |
+17.53% | 31TCr | |
+9.75% | 30TCr | |
+16.08% | 24TCr | |
+2.29% | 22TCr | |
+13.96% | 22TCr | |
+7.95% | 17TCr |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Provides Revenue Guidance for the Year 2022